Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2024-12-27

Clinical Trial Update: A Study of Efficacy and Safety of TLL-018 in CSU Participants [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for TLL-018 in chronic spontaneous urticaria, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TLL-018

Snippet

Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: RECRUITING